Loading…

Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway

[Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbon...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2019-03, Vol.111, p.1166-1175
Main Authors: Chen, Ya-Jing, Kong, Li, Tang, Zhuang-Zhuang, Zhang, Yu-Meng, Liu, Yue, Wang, Tao-Yun, Liu, Yao-Wu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003
cites cdi_FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003
container_end_page 1175
container_issue
container_start_page 1166
container_title Biomedicine & pharmacotherapy
container_volume 111
creator Chen, Ya-Jing
Kong, Li
Tang, Zhuang-Zhuang
Zhang, Yu-Meng
Liu, Yue
Wang, Tao-Yun
Liu, Yao-Wu
description [Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbonyl aldehydes and their detoxicating enzyme glyoxalase 1 (Glo-1) play vital roles in pathogenesis of diabetic complications. The aim of this study was to evaluate the renoprotective effects of hesperetin against DN in rats, and to investigate mechanisms from the aspect of Nrf2/ARE/Glo-1 pathway. Streptozotocin-induced diabetic rats were treated orally with hesperetin (50 and 150 mg/kg), or nuclear factor erythroid-derived-2-like 2 (Nrf2) inducer tert-butylhydroquinone (tBHQ, 25 mg/kg) for 10 weeks. Then proteinuria, creatinine, urea nitrogen, and uric acid were assayed for renal functions, fibronectin and collagen IV levels by immunohistochemistry, as well as periodic acid-Schiff staining and electron microscope observation, were used to assess renal morphology. Glo-1 activity, protein, and mRNA levels and the classic Nrf2/ARE pathway were investigated. Moreover, advanced glycation endproducts (AGEs) and its receptor RAGE, interleukin-1β and tumor necrosis factor-α levels were also examined in the kidney. Hesperetin markedly ameliorated the renal functions and structural changes of diabetic rats, accompanied by up-regulation of Glo-1 as well as inhibition of AGEs/RAGE axis and inflammation. Meanwhile, hesperetin caused significant increases in Nrf2 and p-Nrf2 levels, as well as up-regulation of γ-glutamylcysteine synthetase, a well-known target gene of Nrf2/ARE signaling. Our results demonstrated that hesperetin could slow down the pathological process of DN, and Glo-1 enhancement contributed to the beneficial effects, which was obtained by the activation of Nrf2/ARE pathway.
doi_str_mv 10.1016/j.biopha.2019.01.030
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2188981433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332218382428</els_id><sourcerecordid>2188981433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoWqv_QCRHL7udSfbzIojUDxAF6T1ks7M2Zdtdk626_96UqkdPgcnzzvA-jF0gxAiYzVZxZbt-qWMBWMaAMUg4YBMsU4gygPyQTSBPZSSlECfs1PsVAKSZLI7ZiYQiwUTChKkH8j05GuyG6zW1tnN6IM9rq6swNHxD_dJ1vR6WIw9M-PW8Grk2g_3QIfXGn10jZjev89lbO3ZfutWeOPJd4lOPZ-yo0a2n8593yhZ388XtQ_T0cv94e_MUmSRPhkjXEkQqs8KQAUQoykLoylRJKqoSCxRY5lhARk1WCUxyKclkJJtU1EmoJafsar-2d937lvyg1tYbalu9oW7rlcAirAyVZUCTPWpc572jRvXOrrUbFYLamVUrtTerdmYVoApmQ-zy58K2WlP9F_pVGYDrPUCh5oclp7yxtDFUW0dmUHVn_7_wDcqrivI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2188981433</pqid></control><display><type>article</type><title>Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Chen, Ya-Jing ; Kong, Li ; Tang, Zhuang-Zhuang ; Zhang, Yu-Meng ; Liu, Yue ; Wang, Tao-Yun ; Liu, Yao-Wu</creator><creatorcontrib>Chen, Ya-Jing ; Kong, Li ; Tang, Zhuang-Zhuang ; Zhang, Yu-Meng ; Liu, Yue ; Wang, Tao-Yun ; Liu, Yao-Wu</creatorcontrib><description>[Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbonyl aldehydes and their detoxicating enzyme glyoxalase 1 (Glo-1) play vital roles in pathogenesis of diabetic complications. The aim of this study was to evaluate the renoprotective effects of hesperetin against DN in rats, and to investigate mechanisms from the aspect of Nrf2/ARE/Glo-1 pathway. Streptozotocin-induced diabetic rats were treated orally with hesperetin (50 and 150 mg/kg), or nuclear factor erythroid-derived-2-like 2 (Nrf2) inducer tert-butylhydroquinone (tBHQ, 25 mg/kg) for 10 weeks. Then proteinuria, creatinine, urea nitrogen, and uric acid were assayed for renal functions, fibronectin and collagen IV levels by immunohistochemistry, as well as periodic acid-Schiff staining and electron microscope observation, were used to assess renal morphology. Glo-1 activity, protein, and mRNA levels and the classic Nrf2/ARE pathway were investigated. Moreover, advanced glycation endproducts (AGEs) and its receptor RAGE, interleukin-1β and tumor necrosis factor-α levels were also examined in the kidney. Hesperetin markedly ameliorated the renal functions and structural changes of diabetic rats, accompanied by up-regulation of Glo-1 as well as inhibition of AGEs/RAGE axis and inflammation. Meanwhile, hesperetin caused significant increases in Nrf2 and p-Nrf2 levels, as well as up-regulation of γ-glutamylcysteine synthetase, a well-known target gene of Nrf2/ARE signaling. Our results demonstrated that hesperetin could slow down the pathological process of DN, and Glo-1 enhancement contributed to the beneficial effects, which was obtained by the activation of Nrf2/ARE pathway.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2019.01.030</identifier><identifier>PMID: 30841430</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>AGEs/RAGE axis ; Animals ; Carboxylic Ester Hydrolases - metabolism ; Diabetes Mellitus, Experimental - chemically induced ; Diabetes Mellitus, Experimental - complications ; Diabetes Mellitus, Experimental - metabolism ; Diabetic Nephropathies - drug therapy ; Diabetic Nephropathies - etiology ; Diabetic Nephropathies - metabolism ; Diabetic nephropathy ; Glutamate-Cysteine Ligase - metabolism ; Glycation End Products, Advanced - metabolism ; Glyoxalase 1 ; Hesperetin ; Hesperidin - pharmacology ; Inflammation - drug therapy ; Inflammation - metabolism ; Kidney - drug effects ; Kidney - metabolism ; Lactoylglutathione Lyase - metabolism ; Male ; NF-E2-Related Factor 2 - metabolism ; Nrf2/ARE pathway ; Protective Agents - pharmacology ; Rats ; Rats, Sprague-Dawley ; Signal Transduction - drug effects ; Streptozocin - pharmacology ; Up-Regulation - drug effects</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2019-03, Vol.111, p.1166-1175</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003</citedby><cites>FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30841430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Ya-Jing</creatorcontrib><creatorcontrib>Kong, Li</creatorcontrib><creatorcontrib>Tang, Zhuang-Zhuang</creatorcontrib><creatorcontrib>Zhang, Yu-Meng</creatorcontrib><creatorcontrib>Liu, Yue</creatorcontrib><creatorcontrib>Wang, Tao-Yun</creatorcontrib><creatorcontrib>Liu, Yao-Wu</creatorcontrib><title>Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>[Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbonyl aldehydes and their detoxicating enzyme glyoxalase 1 (Glo-1) play vital roles in pathogenesis of diabetic complications. The aim of this study was to evaluate the renoprotective effects of hesperetin against DN in rats, and to investigate mechanisms from the aspect of Nrf2/ARE/Glo-1 pathway. Streptozotocin-induced diabetic rats were treated orally with hesperetin (50 and 150 mg/kg), or nuclear factor erythroid-derived-2-like 2 (Nrf2) inducer tert-butylhydroquinone (tBHQ, 25 mg/kg) for 10 weeks. Then proteinuria, creatinine, urea nitrogen, and uric acid were assayed for renal functions, fibronectin and collagen IV levels by immunohistochemistry, as well as periodic acid-Schiff staining and electron microscope observation, were used to assess renal morphology. Glo-1 activity, protein, and mRNA levels and the classic Nrf2/ARE pathway were investigated. Moreover, advanced glycation endproducts (AGEs) and its receptor RAGE, interleukin-1β and tumor necrosis factor-α levels were also examined in the kidney. Hesperetin markedly ameliorated the renal functions and structural changes of diabetic rats, accompanied by up-regulation of Glo-1 as well as inhibition of AGEs/RAGE axis and inflammation. Meanwhile, hesperetin caused significant increases in Nrf2 and p-Nrf2 levels, as well as up-regulation of γ-glutamylcysteine synthetase, a well-known target gene of Nrf2/ARE signaling. Our results demonstrated that hesperetin could slow down the pathological process of DN, and Glo-1 enhancement contributed to the beneficial effects, which was obtained by the activation of Nrf2/ARE pathway.</description><subject>AGEs/RAGE axis</subject><subject>Animals</subject><subject>Carboxylic Ester Hydrolases - metabolism</subject><subject>Diabetes Mellitus, Experimental - chemically induced</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Diabetic Nephropathies - etiology</subject><subject>Diabetic Nephropathies - metabolism</subject><subject>Diabetic nephropathy</subject><subject>Glutamate-Cysteine Ligase - metabolism</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Glyoxalase 1</subject><subject>Hesperetin</subject><subject>Hesperidin - pharmacology</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Kidney - drug effects</subject><subject>Kidney - metabolism</subject><subject>Lactoylglutathione Lyase - metabolism</subject><subject>Male</subject><subject>NF-E2-Related Factor 2 - metabolism</subject><subject>Nrf2/ARE pathway</subject><subject>Protective Agents - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Signal Transduction - drug effects</subject><subject>Streptozocin - pharmacology</subject><subject>Up-Regulation - drug effects</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoWqv_QCRHL7udSfbzIojUDxAF6T1ks7M2Zdtdk626_96UqkdPgcnzzvA-jF0gxAiYzVZxZbt-qWMBWMaAMUg4YBMsU4gygPyQTSBPZSSlECfs1PsVAKSZLI7ZiYQiwUTChKkH8j05GuyG6zW1tnN6IM9rq6swNHxD_dJ1vR6WIw9M-PW8Grk2g_3QIfXGn10jZjev89lbO3ZfutWeOPJd4lOPZ-yo0a2n8593yhZ388XtQ_T0cv94e_MUmSRPhkjXEkQqs8KQAUQoykLoylRJKqoSCxRY5lhARk1WCUxyKclkJJtU1EmoJafsar-2d937lvyg1tYbalu9oW7rlcAirAyVZUCTPWpc572jRvXOrrUbFYLamVUrtTerdmYVoApmQ-zy58K2WlP9F_pVGYDrPUCh5oclp7yxtDFUW0dmUHVn_7_wDcqrivI</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Chen, Ya-Jing</creator><creator>Kong, Li</creator><creator>Tang, Zhuang-Zhuang</creator><creator>Zhang, Yu-Meng</creator><creator>Liu, Yue</creator><creator>Wang, Tao-Yun</creator><creator>Liu, Yao-Wu</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway</title><author>Chen, Ya-Jing ; Kong, Li ; Tang, Zhuang-Zhuang ; Zhang, Yu-Meng ; Liu, Yue ; Wang, Tao-Yun ; Liu, Yao-Wu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>AGEs/RAGE axis</topic><topic>Animals</topic><topic>Carboxylic Ester Hydrolases - metabolism</topic><topic>Diabetes Mellitus, Experimental - chemically induced</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Diabetic Nephropathies - etiology</topic><topic>Diabetic Nephropathies - metabolism</topic><topic>Diabetic nephropathy</topic><topic>Glutamate-Cysteine Ligase - metabolism</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Glyoxalase 1</topic><topic>Hesperetin</topic><topic>Hesperidin - pharmacology</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Kidney - drug effects</topic><topic>Kidney - metabolism</topic><topic>Lactoylglutathione Lyase - metabolism</topic><topic>Male</topic><topic>NF-E2-Related Factor 2 - metabolism</topic><topic>Nrf2/ARE pathway</topic><topic>Protective Agents - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Signal Transduction - drug effects</topic><topic>Streptozocin - pharmacology</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Ya-Jing</creatorcontrib><creatorcontrib>Kong, Li</creatorcontrib><creatorcontrib>Tang, Zhuang-Zhuang</creatorcontrib><creatorcontrib>Zhang, Yu-Meng</creatorcontrib><creatorcontrib>Liu, Yue</creatorcontrib><creatorcontrib>Wang, Tao-Yun</creatorcontrib><creatorcontrib>Liu, Yao-Wu</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Ya-Jing</au><au>Kong, Li</au><au>Tang, Zhuang-Zhuang</au><au>Zhang, Yu-Meng</au><au>Liu, Yue</au><au>Wang, Tao-Yun</au><au>Liu, Yao-Wu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2019-03</date><risdate>2019</risdate><volume>111</volume><spage>1166</spage><epage>1175</epage><pages>1166-1175</pages><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>[Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbonyl aldehydes and their detoxicating enzyme glyoxalase 1 (Glo-1) play vital roles in pathogenesis of diabetic complications. The aim of this study was to evaluate the renoprotective effects of hesperetin against DN in rats, and to investigate mechanisms from the aspect of Nrf2/ARE/Glo-1 pathway. Streptozotocin-induced diabetic rats were treated orally with hesperetin (50 and 150 mg/kg), or nuclear factor erythroid-derived-2-like 2 (Nrf2) inducer tert-butylhydroquinone (tBHQ, 25 mg/kg) for 10 weeks. Then proteinuria, creatinine, urea nitrogen, and uric acid were assayed for renal functions, fibronectin and collagen IV levels by immunohistochemistry, as well as periodic acid-Schiff staining and electron microscope observation, were used to assess renal morphology. Glo-1 activity, protein, and mRNA levels and the classic Nrf2/ARE pathway were investigated. Moreover, advanced glycation endproducts (AGEs) and its receptor RAGE, interleukin-1β and tumor necrosis factor-α levels were also examined in the kidney. Hesperetin markedly ameliorated the renal functions and structural changes of diabetic rats, accompanied by up-regulation of Glo-1 as well as inhibition of AGEs/RAGE axis and inflammation. Meanwhile, hesperetin caused significant increases in Nrf2 and p-Nrf2 levels, as well as up-regulation of γ-glutamylcysteine synthetase, a well-known target gene of Nrf2/ARE signaling. Our results demonstrated that hesperetin could slow down the pathological process of DN, and Glo-1 enhancement contributed to the beneficial effects, which was obtained by the activation of Nrf2/ARE pathway.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30841430</pmid><doi>10.1016/j.biopha.2019.01.030</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2019-03, Vol.111, p.1166-1175
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2188981433
source ScienceDirect Freedom Collection 2022-2024
subjects AGEs/RAGE axis
Animals
Carboxylic Ester Hydrolases - metabolism
Diabetes Mellitus, Experimental - chemically induced
Diabetes Mellitus, Experimental - complications
Diabetes Mellitus, Experimental - metabolism
Diabetic Nephropathies - drug therapy
Diabetic Nephropathies - etiology
Diabetic Nephropathies - metabolism
Diabetic nephropathy
Glutamate-Cysteine Ligase - metabolism
Glycation End Products, Advanced - metabolism
Glyoxalase 1
Hesperetin
Hesperidin - pharmacology
Inflammation - drug therapy
Inflammation - metabolism
Kidney - drug effects
Kidney - metabolism
Lactoylglutathione Lyase - metabolism
Male
NF-E2-Related Factor 2 - metabolism
Nrf2/ARE pathway
Protective Agents - pharmacology
Rats
Rats, Sprague-Dawley
Signal Transduction - drug effects
Streptozocin - pharmacology
Up-Regulation - drug effects
title Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A32%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hesperetin%20ameliorates%20diabetic%20nephropathy%20in%20rats%20by%20activating%20Nrf2/ARE/glyoxalase%201%20pathway&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Chen,%20Ya-Jing&rft.date=2019-03&rft.volume=111&rft.spage=1166&rft.epage=1175&rft.pages=1166-1175&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2019.01.030&rft_dat=%3Cproquest_cross%3E2188981433%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-ad3025368cec01108982abcb452b918121971806ef6b214733ec6e3f52d40003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2188981433&rft_id=info:pmid/30841430&rfr_iscdi=true